DOES ADRIAMYCIN INDUCE INTERSTRAND CROSS-LINKS IN DNA

被引:70
作者
CULLINANE, C [1 ]
VANROSMALEN, A [1 ]
PHILLIPS, DR [1 ]
机构
[1] LA TROBE UNIV, DEPT BIOCHEM, BUNDOORA, VIC 3083, AUSTRALIA
关键词
D O I
10.1021/bi00181a025
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Under nonenzymatic conditions in vitro, Adriamycin appears to form interstrand cross-links with DNA over 1-2 days. This is the first report of such Adriamycin-induced interstrand cross-links in vitro. Cross-links were measured by a fluorescence based renaturation assay and also by gel electrophoresis. Both procedures revealed an increase of cross-linking with reaction time and with increasing Adriamycin concentration and a 5-6-fold enhancement in the presence of Fe3+ ions. The cross-link contains the Adriamycin chromophore, with a lambda(max) of 508 nm, intercalated at the GpC site of cross-linking. Maximal stoichiometry of the cross-link was one per 11-20 bp. The cross-link appears to involve adducts of the Adriamycin chromophore linked to the N-2 of guanine, with no indication that N-7 of guanine is involved. Given that the mode of action of Adriamycin still remains obscure, even after 20 years of clinical use, the possibility that interstrand DNA cross-links may be associated with the clinical mechanism of action of this drug should now be fully addressed.
引用
收藏
页码:4632 / 4638
页数:7
相关论文
共 57 条
[1]  
Arcamone F., 1988, ANTHRACYCLINE ANTHRA, P1
[2]   ENHANCEMENT OF DOXORUBICIN TOXICITY FOLLOWING ACTIVATION BY NADPH CYTOCHROME P450 REDUCTASE [J].
BARTOSZEK, A ;
WOLF, CR .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (07) :1449-1457
[3]   IRON(III) ADRIAMYCIN AND IRON(III) DAUNORUBICIN COMPLEXES - PHYSICOCHEMICAL CHARACTERISTICS, INTERACTION WITH DNA, AND ANTITUMOR-ACTIVITY [J].
BERALDO, H ;
GARNIERSUILLEROT, A ;
TOSI, L ;
LAVELLE, F .
BIOCHEMISTRY, 1985, 24 (02) :284-289
[4]  
CHABNER D, 1992, CANCER CHEMOTHERAPY
[5]   INDUCTION OF STABLE TRANSCRIPTIONAL BLOCKAGE SITES BY ADRIAMYCIN - GPC SPECIFICITY OF APPARENT ADRIAMYCIN DNA ADDUCTS AND DEPENDENCE ON IRON(III) IONS [J].
CULLINANE, C ;
PHILLIPS, DR .
BIOCHEMISTRY, 1990, 29 (23) :5638-5646
[6]   STUDIES ON THE INVIVO DISPOSITION OF ADRIAMYCIN IN HUMAN-TUMORS WHICH EXHIBIT DIFFERENT RESPONSES TO THE DRUG [J].
CUMMINGS, J ;
MCARDLE, CS .
BRITISH JOURNAL OF CANCER, 1986, 53 (06) :835-838
[7]   DETERMINATION OF COVALENT BINDING TO INTACT DNA, RNA, AND OLIGONUCLEOTIDES BY INTERCALATING ANTICANCER DRUGS USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - STUDIES WITH DOXORUBICIN AND NADPH CYTOCHROME-P-450 REDUCTASE [J].
CUMMINGS, J ;
BARTOSZEK, A ;
SMYTH, JF .
ANALYTICAL BIOCHEMISTRY, 1991, 194 (01) :146-155
[8]   THE MOLECULAR PHARMACOLOGY OF DOXORUBICIN INVIVO [J].
CUMMINGS, J ;
ANDERSON, L ;
WILLMOTT, N ;
SMYTH, JF .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (05) :532-535
[9]   TRANSFER OF FERRITIN-BOUND IRON TO ADRIAMYCIN [J].
DEMANT, EJF .
FEBS LETTERS, 1984, 176 (01) :97-100
[10]  
DEVITA VT, 1989, CANCER PRINCIPLES PR